Esperion Therapeutics, Inc. (LON:0IIM)
1.815
-0.060 (-3.20%)
At close: Feb 21, 2025
Esperion Therapeutics Employees
Esperion Therapeutics had 240 employees as of December 31, 2023. The number of employees increased by 41 or 20.60% compared to the previous year.
Employees
240
Change (1Y)
41
Growth (1Y)
20.60%
Revenue / Employee
918.48K GBP
Profits / Employee
-269.75K GBP
Market Cap
283.67M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Esperion Therapeutics News
- 9 days ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewsWire
- 2 months ago - Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
- 2 months ago - Esperion Announces $210 Million Convertible Debt Financing - GlobeNewsWire
- 2 months ago - Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel - GlobeNewsWire
- 2 months ago - Will The Long Awaited Breakout For Esperion Therapeutics Hold? - Seeking Alpha
- 3 months ago - Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - GlobeNewsWire
- 3 months ago - Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy - Seeking Alpha